Affinage

ITGB7

Integrin beta-7 · UniProt P26010

Round 2 corrected
Length
798 aa
Mass
86.9 kDa
Annotated
2026-04-28
41 papers in source corpus 21 papers cited in narrative 21 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ITGB7 encodes the integrin β7 subunit, which pairs with either α4 to form α4β7 or with αE (CD103) to form αEβ7, both of which are central to mucosal immune cell trafficking and tissue retention. α4β7 mediates lymphocyte homing to gut-associated lymphoid tissue by binding MAdCAM-1 as its preferential ligand, as well as fibronectin (CS-1 region) and VCAM-1, with adhesive strength bistably regulated by three divalent cation-binding sites (MIDAS, ADMIDAS, LIMBS) in the β7 I-like domain (PMID:7687523, PMID:14608374). The β7 cytoplasmic tail engages filamin A to inhibit migration by suppressing membrane protrusion, talin to activate integrin via the NPXY motif, and Dok-1—recruited by tyrosine phosphorylation—to competitively displace talin and inactivate the integrin (PMID:11781567, PMID:19843520). αEβ7 interaction with E-cadherin at the immunological synapse drives lytic granule polarization in CTLs to promote tumor cell killing, and α4β7 is exploited by HIV-1 gp120 via a V2-loop tripeptide to activate LFA-1 and facilitate viral dissemination (PMID:17325197, PMID:18264102).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 1991 High

    Cloning of β7 revealed it as a new leukocyte-restricted integrin β subunit, establishing the molecular identity of ITGB7 and its tissue-selective expression pattern.

    Evidence cDNA cloning, sequencing, and Northern blot in leukocyte vs. non-leukocyte cell lines

    PMID:2040612

    Open questions at the time
    • Pairing partners and ligands unknown at this stage
    • Protein-level expression across tissues not characterized
  2. 1992 High

    Identification of two β7 heterodimers—α4β7 and αEβ7 (HML-1)—on mucosal lymphocytes defined the combinatorial logic of β7 pairing and showed functional divergence between α4β7 and α4β1 in ligand binding.

    Evidence Immunoprecipitation, N-terminal protein sequencing, cell adhesion assays with blocking antibodies on T and B lymphocytes

    PMID:1372909 PMID:1373725 PMID:1542691

    Open questions at the time
    • Physiological in vivo homing ligand not yet identified
    • αEβ7 ligand unknown
  3. 1993 High

    Discovery that α4β7 is the receptor for the mucosal addressin MAdCAM-1 provided the molecular basis for lymphocyte homing to gut-associated lymphoid tissue, explaining tissue tropism.

    Evidence Antibody blocking assays, adhesion to purified MAdCAM-1 and transfectants, Mn2+ activation

    PMID:7687523

    Open questions at the time
    • Structural basis of MAdCAM-1 recognition unresolved
    • Relative contribution to rolling vs. firm adhesion unclear
  4. 1998 High

    Mapping of TGF-β1 response elements in the ITGB7 promoter explained how mucosal cytokine milieu transcriptionally upregulates β7 to shift integrin usage from α4 to αE pairing.

    Evidence Promoter-reporter deletion analysis, gel-shift assays, genistein inhibition of tyrosine kinase signaling

    PMID:9683663

    Open questions at the time
    • Identity of transcription factors binding TGFBRR1/TGFBRR2 not determined
    • Smad involvement not directly tested
  5. 2001 High

    Identification of filamin A as a strong binding partner of the β7 cytoplasmic tail, and demonstration that this interaction inhibits cell migration, revealed a mechanism by which β7-containing integrins restrain lymphocyte motility.

    Evidence Gain- and loss-of-function mutagenesis of the β7 tail filamin-binding site, migration and membrane protrusion assays

    PMID:11781567

    Open questions at the time
    • In vivo relevance of filamin-mediated migration inhibition not tested
    • Filamin binding vs. talin binding competition not yet mapped
  6. 2003 High

    Mutagenesis of three metal-binding sites (MIDAS, ADMIDAS, LIMBS) in the β7 I-like domain showed that divalent cation occupancy bistably switches α4β7 between rolling and firm adhesion states, providing a structural mechanism for adhesion regulation.

    Evidence Site-directed mutagenesis of metal-binding sites with adhesion assays under defined Ca2+/Mg2+/Mn2+ conditions

    PMID:14608374

    Open questions at the time
    • No crystal structure of β7 I-like domain available
    • How inside-out signals modulate metal-site occupancy unknown
  7. 2003 High

    Systematic mapping of PTB domain interactions with β integrin tails (including β7) established that the NPXY motif is a universal docking site for talin, Dok-1, and other PTB-domain proteins, with class-specific selectivity governing activation vs. inactivation.

    Evidence Recombinant PTB domain binding to integrin tails, NPXY mutagenesis, molecular modeling

    PMID:12606711

    Open questions at the time
    • Phosphorylation-dependent switching between talin and Dok-1 not yet shown
  8. 2003 High

    Peyer's patch dendritic cells were shown to specifically imprint α4β7 and CCR9 expression on T cells, establishing a tissue-specific DC–T cell instruction mechanism for gut homing.

    Evidence DC–T cell co-culture from different anatomical sites, flow cytometry, in vivo homing assays

    PMID:12840763

    Open questions at the time
    • Molecular mediators of imprinting (e.g., retinoic acid) not identified in this study
    • Whether β7 induction is transcriptional or post-transcriptional not resolved
  9. 2007 High

    The αEβ7–E-cadherin interaction was shown to recruit the integrin to the immunological synapse and drive lytic granule polarization in CTLs, establishing a direct mechanistic link between β7 and cytotoxic effector function against tumors.

    Evidence Antibody blocking, siRNA knockdown of E-cadherin, confocal microscopy of synapse, cytotoxicity assays

    PMID:17325197

    Open questions at the time
    • Signaling intermediates between αEβ7 engagement and granule polarization uncharacterized
    • Relevance to non-epithelial tumors not explored
  10. 2008 High

    HIV-1 gp120 was found to bind α4β7 via a V2-loop tripeptide mimicking natural ligands, activating LFA-1 to promote virological synapse formation—revealing viral exploitation of mucosal integrin signaling for dissemination.

    Evidence Purified gp120–α4β7 binding assays, intracellular signaling assays, antibody blocking

    PMID:18264102

    Open questions at the time
    • Structural details of gp120–α4β7 interface not determined
    • In vivo contribution to HIV pathogenesis not established at this point
  11. 2009 High

    NMR analysis of phosphorylated β7 tail demonstrated that tyrosine phosphorylation switches the NPXY motif from talin binding (activating) to Dok-1 binding (inactivating), completing the molecular mechanism of integrin deactivation.

    Evidence NMR with 15N-labeled phosphorylated β7 tail, talin1 D372R mutant, live-cell localization

    PMID:19843520

    Open questions at the time
    • Kinase(s) responsible for β7 tail phosphorylation in vivo not identified
    • Temporal dynamics of this switch during lymphocyte arrest not measured
  12. 2011 High

    Reconstitution showed that mechanical strain in actin–filamin networks enhances β integrin tail binding to filamin A while releasing FilGAP, establishing β7 integrin as part of a force-sensing mechanotransduction module.

    Evidence In vitro reconstituted actin–FLNA–β7 tail system, fluorescence loss after photoconversion, rheology

    PMID:21926999

    Open questions at the time
    • Whether this mechanism operates in mucosal lymphocytes under physiological shear unknown
    • Filamin A conformational change not structurally resolved in this context
  13. 2011 High

    ITGB7 knockdown in multiple myeloma cells reversed cell-adhesion-mediated drug resistance and reduced FAK/Src/Rac1/NF-κB signaling, demonstrating that β7 can drive pro-survival adhesion signaling in a non-classical cancer context.

    Evidence shRNA knockdown, adhesion and migration assays, in vivo xenograft homing, Western blotting for pathway components

    PMID:21474670

    Open questions at the time
    • α subunit partner in myeloma not definitively identified
    • Whether this is a direct FAK-interaction or requires co-receptors not resolved
  14. 2020 Medium

    NRF2 was identified as a direct transcriptional activator of ITGB7 via an ARE in its promoter, downstream of TRIM2/ROS signaling in pancreatic cancer, expanding known transcriptional regulation beyond TGF-β1.

    Evidence ChIP-like NRF2 binding to ITGB7 ARE, promoter-reporter assays, NAC rescue, in vivo tumorigenicity

    PMID:32929153

    Open questions at the time
    • Single-lab finding; independent replication needed
    • Whether NRF2–ITGB7 axis operates in immune cells unknown
    • Direct ARE-ITGB7 binding validated only by overexpression-based ChIP approach

Open questions

Synthesis pass · forward-looking unresolved questions
  • Major open questions include the crystal or cryo-EM structure of β7 I-like domain bound to MAdCAM-1, the in vivo kinase(s) that phosphorylate the β7 tail to trigger talin-to-Dok-1 switching, and whether the filamin A mechanotransduction mechanism operates in mucosal lymphocytes under physiological flow conditions.
  • No high-resolution structure of α4β7–MAdCAM-1 complex
  • In vivo kinase for β7 tail tyrosine phosphorylation unknown
  • Filamin-mediated mechanosensing not validated in gut-homing lymphocytes

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098631 cell adhesion mediator activity 5 GO:0008092 cytoskeletal protein binding 3 GO:0048018 receptor ligand activity 1
Localization
GO:0005886 plasma membrane 6
Pathway
R-HSA-168256 Immune System 5 R-HSA-1500931 Cell-Cell communication 4 R-HSA-1474244 Extracellular matrix organization 2 R-HSA-162582 Signal Transduction 2
Partners
CD4CDH1DOK1FLNAITGA4ITGAEMADCAM1TLN1
Complex memberships
α4β7 integrinαEβ7 integrin

Evidence

Reading pass · 21 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1991 The complete amino acid sequence of integrin β7 was determined from overlapping cDNA clones obtained from leukocyte libraries. The β7 protein is predicted to contain a large extracellular portion, a transmembrane domain, and a cytoplasmic tail, with 32–46% identity to other human integrin β subunits and closest similarity to β2 (CD18). β7 mRNA was detected in T and B cell lines and macrophage-like cell lines but not in non-leukocyte cell lines, and phorbol ester stimulation markedly increased β7 mRNA levels in peripheral T cells. cDNA cloning and sequencing, Northern blot analysis, reverse transcription-PCR The Journal of biological chemistry High 2040612
1992 Integrin α4β7 (also called α4βP) was identified as the β7-containing heterodimer expressed in TK-1 T lymphoma cells and activated peripheral blood T cells. α4β7 functions as a fibronectin receptor that binds to the CS-1 region (not the RGD sequence) of fibronectin, and also supports adhesion to VCAM-1, both of which are markedly enhanced by PMA stimulation. Anti-α4 and anti-β7 antibodies induce homotypic cell clustering. Anti-peptide antiserum and mAb immunoprecipitation, affinity chromatography, cell adhesion assays, antibody blocking The Journal of cell biology High 1372909
1992 A family of β7 integrins on human mucosal lymphocytes was characterized: the HML-1 antigen (αEβ7) and α4β7 both use the β7 chain. The HML-1 α-subunit was designated αE (a novel integrin α chain). TGF-β1 reciprocally regulated HML-1 (αEβ7) and LFA-1 expression. N-terminal protein sequencing of purified HML-1 subunit, biochemical characterization, immunoprecipitation Proceedings of the National Academy of Sciences of the United States of America High 1542691
1992 On the JY B lymphoblastoid cell line expressing α4β7 without α4β1, α4β7 makes little or no contribution to fibronectin or VCAM-1 binding under basal conditions; a minor contribution emerges only after PMA stimulation. α4β1 is the functionally dominant VCAM-1 and fibronectin receptor. This demonstrated that the β subunit partner determines the adhesive specificity of α4 integrins. Northern blotting, immunoprecipitation, cell adhesion assays with blocking antibodies The Journal of biological chemistry High 1373725
1993 α4β7 integrin was identified as the receptor for the mucosal vascular addressin MAdCAM-1. Antibodies to α4 and β7 (but not β2/LFA-1) inhibit lymphocyte binding to purified MAdCAM-1 and to MAdCAM-1 transfectants. Mn2+-induced integrin activation enhances binding. MAdCAM-1 is a preferential ligand for α4β7 over α4β1; α4β7 can also bind VCAM-1 but requires greater integrin activation. Antibody blocking assays, cell adhesion to purified MAdCAM-1 and transfectants, Mn2+ activation Cell High 7687523
1993 α4β7 on human B lymphocytes mediates adhesion to fibronectin and VCAM-1 through distinct epitopes on the integrin. α4β7 expression is absent on resting lymphoid tissue B cells but induced upon activation. α4β7 also participates in homotypic B cell aggregation and co-clusters with α4β1 at fibronectin/VCAM-1-coated surfaces. Immunoprecipitation, cell adhesion assays, antibody blocking, flow cytometry Journal of immunology High 7689608
1998 The β7 integrin gene promoter contains TGF-β1 response regions at nucleotides -509 to -398 (TGFBRR1) and -122 to +32 (TGFBRR2) that drive TGF-β1-induced gene expression. TGF-β1 increases β7 and αE subunit mRNA and M290 (αEβ7) surface expression on T cells while decreasing α4 transcripts. Induced β7 expression is inhibited by the tyrosine kinase inhibitor genistein. TGFBRR1 and TGFBRR2 interact with distinct nuclear protein complexes in a phosphorylation-dependent manner. Promoter-reporter deletion analysis, DNase I hypersensitivity mapping, gel-shift assays, RT-PCR, genistein inhibition Immunogenetics High 9683663
2001 The β7 integrin cytoplasmic tail binds strongly to filamin A, and this tight filamin binding inhibits integrin-dependent cell migration by suppressing transient membrane protrusion and cell polarization. Amino acid substitutions that selectively ablate filamin binding from the β7 tail (or confer it onto β1A) confirm this mechanistic link: increased filamin binding correlates with reduced migration without affecting fibronectin matrix assembly or focal adhesion formation. Mutagenesis mapping of filamin-binding site, cell migration assays, membrane protrusion analysis Nature cell biology High 11781567
2003 Integrin α4β7 adhesiveness is bistably regulated by a linear array of three divalent cation-binding sites in the β7 I-like domain: MIDAS is required for both rolling and firm adhesion; ADMIDAS (adjacent to MIDAS) negatively regulates via Ca2+ to permit rolling; LIMBS positively responds to low Ca2+ to promote firm adhesion. ADMIDAS mutation converts rolling to firm adhesion; LIMBS mutation converts firm adhesion to rolling. Site-directed mutagenesis of metal-binding sites, adhesion assays under defined ionic conditions (Ca2+, Mg2+, Mn2+) Nature structural biology High 14608374
2003 Multiple PTB domain-containing proteins (talin, ICAP1-α, Numb, Dok-1) bind to the NPXY motifs in integrin β cytoplasmic tails via a conserved PTB domain–NPXY ligand interaction. β7 and β3 tail mutations of the NPXY motif block these interactions. Gain- and loss-of-function mutations in the β7 tail confirmed class-specific interactions with particular PTB domains (e.g., Dab, EPS8, tensin show integrin class-specific binding). Recombinant PTB domain binding to integrin tails, mutagenesis, molecular modeling, Co-immunoprecipitation Proceedings of the National Academy of Sciences of the United States of America High 12606711
2003 Peyer's patch dendritic cells selectively imprint gut-homing specificity on T cells by inducing high levels of α4β7 (ITGB7-containing integrin) and CCR9, enabling small intestinal homing. This imprinting is specific to Peyer's patch DCs: peripheral lymph node and spleen DCs induced equivalent activation but did not upregulate α4β7 or gut-homing ability. T cell stimulation with DCs from different anatomical sites, flow cytometry for α4β7 expression, in vivo homing assays Nature High 12840763
2007 αEβ7 (CD103/ITGB7) interaction with E-cadherin on tumor cells promotes antitumor CTL activity by recruiting αEβ7 to the immunological synapse and driving lytic granule polarization and exocytosis. Blocking anti-CD103 antibody or siRNA knockdown of E-cadherin abrogates tumor cell killing. TGF-β1 treatment of CD103- CTL clones upregulates αEβ7 and potentiates cytotoxicity. Antibody blocking, RNA interference, confocal microscopy of immunological synapse, cytotoxicity assays The Journal of experimental medicine High 17325197
2007 Crystal structure of filamin A domains IgFLNa19-21 at 2.5 Å reveals auto-inhibition: the N-terminus of IgFLNa20 forms a β-strand that occupies the integrin β-tail binding site on IgFLNa21. Disrupting this auto-inhibitory IgFLNa20-IgFLNa21 interaction enhances filamin binding to integrin β-tails including β7. X-ray crystallography (2.5 Å), mutagenesis, integrin β-tail binding assays The EMBO journal High 17690686
2008 HIV-1 envelope protein gp120 binds to activated α4β7 integrin via a tripeptide motif in the V2 loop of gp120 that mimics natural α4β7 ligands. Engagement of α4β7 by gp120 on CD4+ T cells rapidly activates LFA-1, facilitating formation of virological synapses for cell-to-cell HIV spreading. Binding assays with purified gp120 and α4β7, intracellular signaling assays, antibody blocking, flow cytometry Nature immunology High 18264102
2009 α4β7high CD4+ T cells are more susceptible to productive HIV-1 infection than α4β7low/neg cells, partly because this subset is metabolically active, CCR5high and CXCR4low. On these cells, α4β7 appears in a complex with CD4, and gp120's specific affinity for α4β7 targets these cells. Flow cytometry, HIV infection assays, co-immunoprecipitation of α4β7 with CD4 Proceedings of the National Academy of Sciences of the United States of America High 19933330
2009 Tyrosine phosphorylation of the β7 integrin cytoplasmic tail is a conserved mechanism for regulating integrin activation. Talin1 binds to the NPXY motif and membrane-proximal portion of β7 tail, and tyrosine phosphorylation decreases talin affinity while greatly increasing Dok1 affinity (restricted to the NPXY region). Dok1 acts as a talin competitor that does not form activating membrane-proximal interactions, thereby inhibiting integrin activation. NMR-based protein-protein interaction assay with 15N-labeled phosphorylated β7 tail, mutagenesis, talin1 D372R mutation and live cell localization The Journal of biological chemistry High 19843520
2011 ITGB7 silencing in multiple myeloma (MM) cells reduces adhesion to fibronectin and E-cadherin, reverses cell-adhesion-mediated drug resistance to bortezomib and melphalan, abrogates SDF1α-driven transwell migration, reduces vessel density in xenografts, and alters in vivo BM homing. Mechanistically, ITGB7 knockdown inhibits FAK and Src phosphorylation, Rac1 activation and SUMOylation, reduces VEGF production in MM–BM stem cell co-cultures, and attenuates p65-NF-κB activity. shRNA knockdown, cell adhesion assays, transwell migration, in vivo xenograft and homing assays, Western blotting for FAK/Src/Rac1/NF-κB Blood High 21474670
2011 Mechanical strain in actin networks differentially regulates binding of β-integrin cytoplasmic tails and FilGAP to filamin A (FLNA). Strain increases β-integrin tail binding to FLNA while causing FilGAP to dissociate, providing a direct molecular basis for mechanotransduction. The β7 integrin tail was used in the reconstituted minimal system (actin + FLNA + β-integrin tail + FilGAP). In vitro reconstitution with purified components, fluorescence loss after photoconversion, rheological measurement of actin network strain Nature High 21926999
2020 In pancreatic cancer, TRIM2 activates NRF2 via ROS signaling, and NRF2 directly binds to an antioxidant response element (ARE) in the ITGB7 promoter to enhance ITGB7 transcription. ITGB7 in turn activates the FAK pathway. Antioxidant N-acetyl-L-cysteine treatment reduces ROS, NRF2, and ITGB7 levels; NRF2 nuclear translocation rescues inhibited ITGB7 transcription. siRNA/shRNA knockdown, NAC antioxidant treatment, promoter-reporter assay, ChIP-like NRF2 binding to ARE, Western blotting, in vivo tumorigenicity assays Oncogene Medium 32929153
2019 Recombinant HPV16 capsid protein L2 (rVL2) suppresses glucose metabolism in cervical cancer cells by inhibiting the ITGB7/C/EBPβ signaling pathway, reducing expression of GLUT1, LDHA, and ALDOA. Inhibition of ITGB7 mediates rVL2-induced decreases in glucose uptake and lactate production, and consequent inhibition of proliferation. Gene-chip assay, RT-PCR, Western blot, glucose uptake and lactate production assays, in vivo animal model OncoTargets and therapy Medium 31819523
2008 In the pregnant mouse uterus, ITGB7-positive decidual leukocytes are predominantly dendritic cells forming three phenotypically distinct subsets defined by differential expression of ITGA4/ITGB7 vs. ITGAE/ITGB7. These subsets reside in distinct uterine microdomains: ITGA4/ITGB7+ DCs localize to the vascular zone and make direct contact with uterine NK cells, while ITGAE/ITGB7+ DCs localize to the central decidua basalis and myometrium. Multiparameter flow cytometry, confocal microscopy Biology of reproduction Medium 18562709

Source papers

Stage 0 corpus · 41 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2002 Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proceedings of the National Academy of Sciences of the United States of America 1479 12477932
1993 Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1287 7687523
2003 Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 847 12840763
2021 Dual proteome-scale networks reveal cell-specific remodeling of the human interactome. Cell 705 33961781
2011 Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Briefings in bioinformatics 656 21873635
2008 HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nature immunology 442 18264102
2004 The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome research 438 15489334
2012 HIV: cell binding and entry. Cold Spring Harbor perspectives in medicine 416 22908191
2017 Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nature biotechnology 378 28319085
1992 Role of integrin alpha 4 beta 7/alpha 4 beta P in lymphocyte adherence to fibronectin and VCAM-1 and in homotypic cell clustering. The Journal of cell biology 345 1372909
2003 Integrin beta cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling. Proceedings of the National Academy of Sciences of the United States of America 341 12606711
2012 Novel genetic loci identified for the pathophysiology of childhood obesity in the Hispanic population. PloS one 312 23251661
2011 Mechanical strain in actin networks regulates FilGAP and integrin binding to filamin A. Nature 277 21926999
2009 The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proceedings of the National Academy of Sciences of the United States of America 244 19933330
1992 A family of beta 7 integrins on human mucosal lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 237 1542691
1992 Adhesion to vascular cell adhesion molecule 1 and fibronectin. Comparison of alpha 4 beta 1 (VLA-4) and alpha 4 beta 7 on the human B cell line JY. The Journal of biological chemistry 235 1373725
2007 Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. The Journal of experimental medicine 222 17325197
2010 MHC class II-associated proteins in B-cell exosomes and potential functional implications for exosome biogenesis. Immunology and cell biology 221 20458337
2009 A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication. The Journal of biological chemistry 211 19460752
2001 Increased filamin binding to beta-integrin cytoplasmic domains inhibits cell migration. Nature cell biology 200 11781567
2011 Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood 141 21474670
1993 Alpha 4 beta 7 integrin mediates B cell binding to fibronectin and vascular cell adhesion molecule-1. Expression and function of alpha 4 integrins on human B lymphocytes. Journal of immunology (Baltimore, Md. : 1950) 132 7689608
2007 Structure of three tandem filamin domains reveals auto-inhibition of ligand binding. The EMBO journal 129 17690686
2003 Bistable regulation of integrin adhesiveness by a bipolar metal ion cluster. Nature structural biology 129 14608374
2011 Memory CCR6+CD4+ T cells are preferential targets for productive HIV type 1 infection regardless of their expression of integrin β7. Journal of immunology (Baltimore, Md. : 1950) 122 21398606
2013 Structural basis for endosomal trafficking of diverse transmembrane cargos by PX-FERM proteins. Proceedings of the National Academy of Sciences of the United States of America 121 23382219
2011 The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7) +/CD4+ T cells as key targets in mucosal transmission. PLoS pathogens 119 21383973
2005 L-selectin, alpha 4 beta 1, and alpha 4 beta 7 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine. Journal of immunology (Baltimore, Md. : 1950) 110 15699171
1991 Complete amino acid sequence of an integrin beta subunit (beta 7) identified in leukocytes. The Journal of biological chemistry 108 2040616
2009 Beta integrin tyrosine phosphorylation is a conserved mechanism for regulating talin-induced integrin activation. The Journal of biological chemistry 103 19843520
1998 The beta7 integrin gene (Itgb-7) promoter is responsive to TGF-beta1: defining control regions. Immunogenetics 46 9683663
2020 Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. Oncogene 34 32929153
2018 Genome-Wide Association Study Confirming a Strong Effect of HLA and Identifying Variants in CSAD/lnc-ITGB7-1 on Chromosome 12q13.13 Associated With Susceptibility to Fulminant Type 1 Diabetes. Diabetes 32 30552108
2021 Integrated analysis reveals the participation of IL4I1, ITGB7, and FUT7 in reshaping the TNBC immune microenvironment by targeting glycolysis. Annals of medicine 26 34134578
2022 EccDNA-oriented ITGB7 expression in breast cancer. Annals of translational medicine 11 36660685
2019 Recombinant Viral Capsid Protein L2 (rVL2) of HPV 16 Suppresses Cell Proliferation and Glucose Metabolism via ITGB7/C/EBPβ Signaling Pathway in Cervical Cancer Cell Lines. OncoTargets and therapy 11 31819523
2021 Circulating MAdCAM-1 and ITGB7 in Patients with Plaque Psoriasis and Eruptive Lichen Planus-Preliminary Data. Biology 10 34827121
2008 Identification of ITGA4/ITGB7 and ITGAE/ITGB7 expressing subsets of decidual dendritic-like cells within distinct microdomains of the pregnant mouse uterus. Biology of reproduction 10 18562709
2026 Epigenetic Regulation of ITGB7 Promotes Coronary Heart Disease via Immune and Metabolic Pathways: A Multimodal Mendelian Randomization Study. Cardiovascular therapeutics 0 41509664
2025 Retrospective detection of ITGB7 gene mutation in a holstein calf with chronic diarrhea that was suspected of hereditary cholesterol deficiency. The Journal of veterinary medical science 0 39814374
2025 ITGB7 Remodels Inflammation and Immune Microenvironment and Enhances Checkpoint Inhibitor-Based Immunotherapy in Pancreatic Cancer. Journal of inflammation research 0 41426254